Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Correlation of EZH2 and related signaling molecules p-STAT3, p-ERK1/2, and MYC overexpression with H3K27 trimethylation associates differently to disease progression in JAK2 mutation -positive and -negative myeloid neoplasms
Flerova, Elizaveta , Chai, Jiani , Gong, Jerald Z., Wang, Yanhua, Tian, Xuejun , Choudhuri, Jui

Mayo Clinic

Leukemia & Lymphoma | December 31, 2025 | Volume: 67 | Issue: 4 | Pages: 832-845

10.1080/10428194.2025.2609752 | PMID 41474263 Get It

Real-World Indirect Treatment Comparison of Terlipressin vs Midodrine Plus Octreotide in Hepatorenal Syndrome-Acute Kidney Injury
Allegretti, Andrew S. , Chirikov, Viktor , Wang, Wei‐Jhih , Huang, Xingyue , Moore, Kevin, Gonzalez, Stevan A , Allegretti, Andrew S , Simonetto, Douglas A , Simonetto, Douglas A. , Moore, Kevin

Mayo Clinic

Clinical and Translational Gastroenterology | December 31, 2025 | Volume: 17 | Issue: 2 | Pages: e00951

10.14309/ctg.0000000000000951 | PMID 41472624 Get It

INTRODUCTION: Evidence on the comparative real-world effectiveness of terlipressin vs midodrine plus octreotide (MO) for hepatorenal syndrome-acute kidney injury (HRS-AKI) in the United Kingdom and the United States is limited. METHODS: Using individual-level chart review data for patients across the United Kingdom (2013–2017) and the United States (2016–2019), an indirect treatment comparison was conducted comparing the efficacy of terlipressin (UK cohort) with MO (US cohort). Covariate balancing propensity scoring matched the cohorts on baseline serum creatinine (SCr), presence of encephalopathy and/or ascites, albumin use and duration, age, and sex. The primary endpoint was HRS reversal, defined as achieving SCr ≤1.5 mg/dL by the last day of treatment. RESULTS: At treatment initiation, 90.2% of UK patients received terlipressin (194/215), while 89.2% of US patients received MO (140/157). Concomitant albumin was administered in 67.9% of UK and 98.7% of US patients. In a covariate balancing propensity score-adjusted cohort, HRS reversal was achieved in 53.2% of terlipressin-treated patients (the United Kingdom, weighted effective sample size of 75) compared with 16.9% of MO-treated patients (the United States, n = 89) (adjusted mean difference (95% CI) 36.3% (22.4, 50.2), P < 0.0001). In adjusted analysis, individuals treated with terlipressin experienced an overall reduction in SCr at completion of treatment (SCr decrease 1.00 mg/dL vs increase of 0.08 mg/dL for MO-treated patients, P < 0.0001). DISCUSSION: HRS-AKI treatment and outcomes differ between the United Kingdom and the United States, attributed to the historical standard of care MO in the United States. In adjusted analyses, real-world use of terlipressin was more effective than MO at improving kidney function and achieving HRS-AKI reversal.
Primary Breast MALT Lymphoma: Clinical Features and Outcomes From a Single‐Institution Experience at Mayo Clinic
Alnughmush, Ahmed , Atallah‐Yunes, Suheil Albert , Hellou, Tamer , Habermann, Thomas M., Wang, Yucai, Munoz, Javier, Madiha, Iqbal, King, R., Breen, William G. , Villasboas, Jose C., Witzig, Thomas E., Ansell, S. M., Nowakowski, Grzegorz S. , Habermann, Thomas M. , Habermann, Thomas , Atallah-Yunes, Albert , Witzig, T.E. , Ansell, Stephen M.

Mayo Clinic

American Journal of Hematology | December 30, 2025 | Volume: 101 | Issue: 3 | Pages: 639-643

10.1002/ajh.70178 | PMID 41462033 Get It

Ebola virus matrix protein VP40 triggers inflammatory responses linked to the ebolavirus virulence
Yamaoka, Satoko , Mhamdi, Zeineb, Wang, Lin , Swenson, Vaille A. , McNally, Kristin L., Lu, Shao‐Chia , Singh, Reema , Saundh, Stephanie L. , Zell, Brady N. , Best, Sonja M. , Barry, Michael A , Ebihara, Hideki , Yamaoka, Satoko , Zell, Brady , Wang, Lin , Barry, Michael A. , Rasmussen, Angela L , Ebihara, Hideki

Mayo Clinic

Proceedings of the National Academy of Sciences | December 29, 2025 | Volume: 123 | Issue: 1 | Pages: No page available

10.1073/pnas.2508194123 | PMID 41461033 Get It

Uncontrolled systemic inflammatory responses are a critical pathological feature of fatal Ebola virus (EBOV) infection. While some inflammatory responses may originate from mononuclear phagocytes (MNPs), nonimmune cells vastly outnumber MNPs and may be an important source of inflammation. Here, we demonstrated that highly virulent EBOV induced a high and sustained pro-inflammatory response compared to less virulent ebolaviruses in non-MNPs through TLR4-independent NF-κB activation. We identified the EBOV matrix protein VP40 as a potent activator of NF-κB in non-MNPs, whose intrinsic inflammatory activation ability is higher than VP40 proteins from less virulent ebolaviruses. This suggests that VP40 is a virulence determinant inducing distinct degrees of pro-inflammatory responses among ebolaviruses. Mechanistically, VP40 activated the NF-κB signaling pathway, primarily via TNFR1 using a ligand-independent mechanism. These findings reveal mechanisms that may drive systemic inflammation and promote EBOV pathogenesis, suggesting potential therapeutic strategies to mitigate immune dysregulation in severe EBOV infections.
Assessment of Structured Tele-Critical Care Training and Its Impact on Clinician's Perceptions of Delivery of Care: A Survey-Based Pilot Study
Motayar, Nasim , Xiao, Huijun , Wang, Xiaofeng F., Hassaballa, Hesham A., Griffiths, Carrie L. , Scruth, Elizabeth , Winterbottom, Fiona , Conley, Rebecca, Medford, Whitney , Raikhelkar, Jayashree , Hakimi, Ryan, Everhart, Sonia , Holder, Andre L. , Laudański, Krzysztof

Mayo Clinic

Critical Care Explorations | December 29, 2025 | Volume: 8 | Issue: 1 | Pages: e1351

10.1097/cce.0000000000001351 | PMID 41460511 Get It

OBJECTIVES: Current research does not address the existence and impact of structured tele-critical care (TCC) training on the delivery of care in the ICU. This pilot study aimed to evaluate the association between on boarding elements focused on training and clinicians perceptions of delivery of care. DESIGN: Cross-sectional survey study. SETTING AND PARTICIPANTS: Critical Care professionals at four U.S. hospitals, professional meetings and Society of Critical Care Medicine’s International Membership base. Participants were active clinicians who practice in the TCC setting. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: A total of 432 participants responded to the survey, 227 met the eligibility criteria (52.5%) and were included in the analysis. Respondents were a multi-professional group of TCC clinicians aged between 35–55 years of age (56.4%). Seventy-four percent of respondents reported having orientation before providing TCC, 46% reported having formal mentorship, and 66% reported formal training on their institutional platform. Provision of orientation before participating in a TCC program was associated with higher ratings of feeling prepared (odds ratio [OR], 3.52; p < 0.001) and feeling accepted as part of the ICU team (OR, 2.21; p = 0.008). Mentorship was associated with feeling more prepared (OR, 8.2; p < 0.001) and higher comfort in delivering care (OR, 2.78; p = 0.016). Platform training was associated with feeling more prepared (OR, 4.66; p < 0.001), comfortable in delivering care (OR, 3.6; p = 0.002), feeling accepted as part of the team (OR, 3.18; p < 0.001), and more likely to participate in quality improvement (OR, 2.51; p = 0.001). A site visit also made a positive impact in feeling prepared (OR, 2.86; p < 0.001), comfortable (OR, 4.95; p = 0.002), feeling like recommendations were accepted (OR, 3.73; p < 0.001), more likely to recommend TCC (OR, 3.18; p = 0.001), and participating in quality improvement (OR, 3.24; p < 0.001). CONCLUSIONS: In this pilot study, structured training utilizing orientation, mentorship, and platform training as surrogates, along with a site visit before beginning delivery of care in a TCC setting, were associated with more positive perceptions in the delivery of care domains assessed. We highlight potentially important factors that warrant further evaluation and assessment of the need for standardization across TCC programs.
Validation of Amyloid Chronicity in Autosomal Dominant Alzheimer Disease
Christian, Bradley T, Schultz, Stephanie A. , Barthélemy, Nicolas R., Ryan, Natalie S. , Renton, Alan E., Vermunt, Lisa, Joseph‐Mathurin, Nelly, Shirzadi, Zahra , Strain, Jeremy F. , Chrem, Patricio, Daniels, Alisha , Chhatwal, Jasmeer P. , Cruchaga, Carlos, Ibanez, Laura, Jucker, Mathias, Day, Gregory S, Lee, J.R, Supnet‐Bell, Charlene, Xiong, Chengjie, Schindler, Suzanne E., Wang, Guoqiao, Li, Yan, Koeppe, Robert A., Jack, Clifford R., Morris, John C., Bateman, Randall J., Benzinger, Tammie L.S., Gordon, Brian A., (DIAN), The Dominantly Inherited Alzheimer Network, Wisch, Julie K. , McKay, Nicole S. , Zammit, Matthew D. , Christian, Bradley T. , Millar, Peter R , Barthélemy, Nicolas R. , Renton, Alan , Vermunt, Lisa , Joseph‐Mathurin, Nelly , Cruchaga, Carlos , Ibanez, Laura , Jucker, Mathias , Day, Gregory S. , Xiong, Chengjie , Llibre‐Guerra, Jorge J. , Aguillon, David , Roh, Jee Hoon , Xiong, Chengjie , Schindler, Suzanne E. , Wang, Guoqiao , Li, Yan , Koeppe, Robert A., Jack, Clifford R. , Morris, John C. , McDade, Eric , Bateman, Randall J. , Benzinger, Tammie L.S. , Ances, Beau M. , Betthauser, Tobey J. , Gordon, Brian A.

Mayo Clinic

Alzheimer's & Dementia | December 26, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_103008 Get It

Abstract Background Alzheimer Disease (AD) pathology evolves over decades, and understanding this progression is critical to the understanding of the disease and timing therapeutic interventions. Since individuals with Autosomal Dominant AD (ADAD) develop symptoms around the same age as their parent, it is possible to predict symptom onset and stage individuals by their estimated years to symptom onset (EYO). This approach does not generalize to other forms of AD, thus there is a pressing need for the timecourse of ADAD to be defined in broadly relevant terms. The objective of this project is to validate the Sampled Iterative Local Approximation (SILA) algorithm in a cohort with a known disease timecourse. SILA generates an estimate of time from amyloid positivity (A time ) based on longitudinal PET data. Method We evaluated A time in a longitudinal ADAD sample ( N = 316) with PET PiB data in three ways. First, we compared predicted age at amyloid positive (A+) to observed age at A+ for individuals who became A+ during enrollment. Next, using linear regression, we compared estimated age at A+ to estimated age at symptom onset (EYO=0). Finally, we used generalized additive models to compare the amount of variance in concurrent cognitive performance explained both A time and EYO. Result We observed a mean average error of 1.15 years between actual age at A+ ( N = 26) and the SILA‐predicted A time . Across all participants, SILA‐estimated age at A+ explained 39% of the variance in estimated age at symptom onset ( β = 0.918, p < 0.0001). Finally, we observed a nonlinear association between cognition and both A time and EYO. A time explained 19% of the variance in the general cognitive composite while EYO explained 43% of the variance. Conclusion SILA produces a valid estimate of time‐from‐amyloid positivity in ADAD. This work allows for disease stage in ADAD to be compared to staging for broad forms of AD, which was not previously possible using EYO. However, this work also illustrates that there is a high degree of heterogeneity in preclinical disease duration that is not explained by amyloid alone.
Cutaneous Phosphorylated Alpha‐Synuclein in Lewy Body Dementia
Gibbons, Christopher H. , Levine, Todd, Bellaire, Bailey, Wang, Ningshan , Agarwal, Pinky , Aldridge, Georgina M. , Barboi, Alexandru, Claassen, Daniel O., Evidente, Virgilio G. H., Galasko, Douglas R., Gonzalez‐Duarte, Alejandra, Gil, Ramon, Gudesblatt, Mark , Khemani, Pravin , Kumar, Rajeev , Lamotte, Guillaume, Liu, Andy , Miglis, Mitchell G. , Reynolds, Adam , Sahagian, Gregory A., Saint‐Hilaire, Marie‐Helene, Schwartzbard, Julie, Yerstein, Oleg , Freeman, Roy, Claassen, Daniel O. , Liu, Andy , Claassen, Daniel , Miglis, Mitchell G , Singer, Wolfgang , Soileau, Michael J , Vernino, Steven , Freeman, Roy L. , Kaufmann, Horacio , Gibbons, Christopher , Adler, Charles H. , Evidente, Virgilio Gerald H. , Galasko, Douglas , González-Duarte, Alejandra , Isaacson, Stuart , Lamotte, Guillaume , McFarland, Nikolaus R. , Reynolds, Adam, Sahagian, Gregory , Vernino, Steven , Millar Vernetti, Patricio

Mayo Clinic

Annals of Clinical and Translational Neurology | December 26, 2025 | Volume: 13 | Issue: 5 | Pages: 1041-1051

10.1002/acn3.70291 | PMID 41449577 Get It

ABSTRACT Objective To determine the test performance of cutaneous phosphorylated alpha‐synuclein (P‐SYN) in dementia with Lewy bodies (DLB), individuals with reduced Montreal Cognitive Assessment (MoCA) and healthy controls. Methods This is the first subgroup analysis of the Synuclein‐One study, a prospective, blinded study evaluating P‐SYN detection from skin biopsies in 218 subjects with a referral diagnosis of control ( N = 151) and DLB ( N = 67). All subjects completed detailed examinations, questionnaires, and had skin biopsies for detection of P‐SYN. DLB patients were included if meeting the 4th DLB consensus probable criteria. Control subjects, aged 40–99, had no history, examination findings, or symptoms suggestive of a synucleinopathy or neurodegenerative disease. An expert review panel, blinded to pathological data, determined the final diagnosis. Controls with reduced MoCA (MoCA < 26, N = 26) at screening were analyzed separately. Results After expert panel review, only 50/67 patients met consensus criteria for DLB, 26/151 controls had a reduced MoCA, and 120/151 controls had a normal MoCA. The proportions of subjects with cutaneous P‐SYN detected by skin biopsy were 96.0% (48 of 50) of the DLB group, 31% (8 of 26) of the controls with reduced MoCA, and 3.3% (4 of 120) of the controls with normal MoCA. Interpretation In this prospective, blinded, cross‐sectional study, a high proportion of subjects meeting clinical consensus criteria for DLB had P‐SYN detected in skin biopsies. Almost 1/3 of subjects with reduced MoCA testing also had P‐SYN detected. These results support a role for skin biopsy detection of P‐SYN in patients with DLB. Trial Registration NCT04700722
Targeted plasma eQTL and pQTL analyses to identify potential novel biomarkers for Alzheimer's Disease in African Americans
Badillo, Vanessa M. Colon, Reddy, Joseph S. , Jin, Jiangli , Lincoln, Sarah, Ho, Charlotte C.G. , Wang, Xue, Malphrus, Kimberly G., Nguyen, Thuy T., Polanco, Jean M Marrero, Tamvaka, Nicole , Lachner, Christian, Day, Gregory S, Lucas, John A., Graff‐Radford, Neill R., Ertekin‐Taner, Nilüfer, Carrasquillo, Minerva M., Crook, Julia E. , Wang, Xue, Nguyen, Thuy T. , Kuchenbecker, Lindsey A. , Marrero‐Polanco, Jean , Lachner, Christian , Day, Gregory S. , Lucas, John A. , Graff‐Radford, Neill R. , Ertekin‐Taner, Nilüfer , Carrasquillo, Minerva M.

Mayo Clinic

Alzheimer's & Dementia | December 26, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_104423 Get It

Abstract Background African Americans (AA) are twice as likely to develop dementia than non‐Hispanic Whites but remain underrepresented in Alzheimer's Disease (AD) research. Recent studies have identified AA specific risk factors for AD. Therefore, targeted biomarkers and/or therapies may be needed to effectively treat AD in AA. In this study, we aimed to determine if genetic variants that show association with AD‐risk, plasma transcript or protein levels in AA, may serve as accurate and accessible AD biomarkers. Method In 189 clinically diagnosed AA AD cases and 183 AA cognitively unimpaired (CU) controls, we performed targeted DNA sequencing of 10 AD‐associated loci. Genetic variants at these loci were tested for association with corresponding plasma transcripts and total tau protein levels previously measured in this cohort using a custom nanoString panel and Simoa assays, respectively. Utilizing phased haplotypes (SHAPEIT4) from target sequencing, we inferred local ancestry (RFMix v2) using five superpopulations from the 1000 Genomes Project as anchors. Subsequently, we tested the association of each ancestry specific allelic dosages with endophenotypes using Tractor. In receiver operating characteristic (ROC) analyses, the most significant e/pQTLs were added sequentially to a base model that included age and sex to identify e/pQTLs that improved the accuracy to correctly classify AD cases and CU controls. Result Of the 5,112 variants that were tested, 70 were nominally associated with AD‐risk and with plasma transcript or protein levels. Seven of these 70 variants also showed nominally significant associations of AD‐risk and transcript levels with either African or East Asian local ancestry. ROC analysis of age, sex, 33 e/pQTLs in APOE , SORL1 , TLR4 , EPHA1 , ABCA7 , CLU , and CR1 , and plasma levels of APP, ABCA7, AKAP9, CD14, CLU, and APOE ‐ɛ4 dosage achieved 88.2% area under the curve to discriminate AD vs. CU, a 30.4% improvement over the base model that only included age and sex. Conclusion Plasma transcript levels and e/pQTLs are promising diagnostic biomarkers for AD that may improve accessibility and reduce costs for a more accurate diagnosis of AD.
Exploring the Impact of the APOE3‐Christchurch Mutation on APOE Biology Using iPSC‐derived Cortical Organoids
Gjelsteen, Andrew Keaton, Lu, Wenyan, Martínez, Paula Rodríguez, Marsh, Jacob, Crow, A. , Martens, Yuka A. , Inoue, Yasuteru , Wang, Hu , Bu, GuoJun, T.C.W., Julia, Kanekiyo, Takahisa , Raulin, Ana‐Caroline , Martinez, Paula Rodriguez, Marsh, Jacob A. , Wang, Hu, Han, Xianlin , Karch, Celeste M. , Bu, Guojun , TCW, Julia

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S1 | Pages: No page available

10.1002/alz70855_107229 Get It

Abstract Background The rare APOE3 ‐Christchurch ( APOE3Ch ) variant is associated with remarkable protective effects, delaying the age at onset of PSEN1 ‐E280A driven autosomal dominant Alzheimer's disease (AD). While much of the research on APOE3C h has focused on its role in AD, little is known about how this variant impacts APOE biology under non‐disease conditions. Using cortical organoids as a model system, we aim to investigate the fundamental mechanisms by which APOE3Ch alters APOE biology, including its effects on metabolism and cellular interactions, to better understand its unique properties and potential implications for broader applications. Method Cortical organoids were derived from the isogenic neurodegeneration iPSC line series, with either the APOE3 or APOE3Ch genotype. Single‐cell RNA sequencing (scRNA‐seq) was performed on three independent batches of 6‐month‐old cerebral organoids to identify pathways differentially regulated by APOE3Ch. To further investigate APOE lipidation and its effects on lipid metabolism, lipidomics analysis was conducted on 8‐month‐old cerebral organoids, offering additional insights into APOE3Ch ‐specific biological mechanisms. Validation was also carried out using iPSC‐derived astrocytes and neurons to confirm key findings. Result ScRNA‐seq revealed differences in cell populations and astrocyte subtypes between APOE3 and APOE3Ch organoids, with mitochondrial‐related pathways differentially regulated in APOE3Ch cerebral organoids. These findings were validated in iPSC‐derived astrocytes. APOE3Ch iPSC‐derived astrocytes exhibited increased APOE secretion compared to APOE3 . They also demonstrated enhanced mitochondrial function, as evidenced by increased spare respiratory capacity measured by Seahorse stress assays. Furthermore, APOE3Ch astrocytes showed reduced lipid droplet formation following oleic acid treatment. Lipidomics analysis of APOE3Ch cerebral organoids revealed decreased cholesterol ester levels, suggesting alterations in lipid metabolism. Conclusion Our findings provide novel insights into how the APOE3Ch variant alters APOE biology, revealing differences in mitochondrial function and lipid metabolism. The differential regulation of mitochondrial pathways in APOE3Ch cerebral organoids, along with the enhanced mitochondrial capacity and altered lipid metabolism observed in APOE3Ch astrocytes, highlights the unique properties of this variant. These results offer valuable mechanistic understanding that may inform future therapeutic strategies targeting APOE biology, particularly in the context of AD.
Blood‐based genes and co‐expression network levels are associated with AD/MCI diagnosis, cognitive, and neuroimaging phenotypes and preserved in the brain
Chen, Xuan, Wang, Xue, Reddy, Joseph S. , Quicksall, Zachary , Nguyen, Thuy T., Reyes, Denise Alexandra Chavez, Lowe, Val J. , Petersen, R. C., Kantarci, Kejal, Nho, Kwangsik, Allen, Mariet , Carrasquillo, Minerva M., Saykin, Andrew Joel, Ertekin‐Taner, Nilüfer, Wang, Xue, Nguyen, Thuy T. , Petersen, Ronald, Kantarci, Kejal , Nho, Kwangsik T. , Carrasquillo, Minerva M. , Saykin, Andrew J. , Ertekin‐Taner, Nilüfer

Mayo Clinic

Alzheimer's & Dementia | December 25, 2025 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_100329 Get It

Abstract Background Most existing biomarkers for Alzheimer's disease (AD) inform on core AD pathologies in the central nervous system, namely amyloid, tau and neurodegeneration (ATN). However, molecular disease mechanisms underlying AD are complex and heterogeneous, highlighting the need for cost‐effective blood‐based biomarkers that reflect brain molecular changes in AD beyond ATN. Method Using peripheral blood transcriptome data from the Mayo Clinic Study of Aging(MCSA) and the Alzheimer's Disease Neuroimaging Initiative, we identified genes associated with AD or mild cognitive impairment (MCI) diagnosis, cognitive, and harmonized neuroimaging measures in two cohorts, followed by meta‐analysis. We identified consensus gene co‐expression modules in MCSA and ADNI using WGCNA and assessed the association between module eigengenes and aforementioned measures. Using seven bulk brain RNAseq cohorts, we confirmed the preservation of coexpression modules across blood and brain. Enrichment analyses of Gene Ontology (GO) terms and cell‐types were performed using significant and/or hub genes. The MCSA transcriptome was further deconvoluted to obtain cell‐type proportions and cell‐type specific expression. Result Blood transcriptome modules M5 and M8 are upregulated in AD/MCI and associate with worse cognition, whereas M1, M10, M13, M16, and M21 are downregulated in AD/MCI and associate with better cognition. M17 associates with more microhemorrhages. Cell‐type enrichment analysis revealed that M5 is enriched in basophils, monocytes, and neutrophils; M8 in monocytes and neutrophils; M13 in natural kills cells; M17 in megakaryocytes; M21 in B cells. GO analysis shows broad consistency with the cell‐type enrichment analysis. M1, 5, and 8 are preserved in the brain network modules. From these modules, we prioritized transcripts significantly associated with at least one AD‐related phenotype in both blood and brain. Cell‐type deconvolution analysis shows that prioritized transcripts in M1 associate with better cognition and higher metabolic activity in B cells. Conclusion We identified blood transcripts and modules associated with AD/MCI, cognition, or neuroimaging, with three preserved in brain networks. These three modules represent centrally linked peripheral molecular signatures that can reveal perturbed brain pathways and cell level transcriptional changes in AD/MCI. We aim to further investigate the prioritized transcripts in additional datasets to establish them as potential novel biomarkers and therapeutic targets.